Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders.
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of patients recovering from non-elective hip fracture surgery. The Company’s second program is focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta, or TRß, for adrenoleukodystrophy, or ALD, and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis, or NASH. Viking is also developing additional programs targeted at diabetes, metabolic diseases and anemia.